Siglec-15 Enhances Cisplatin Resistance in Cervical Cancer Cells by Promoting Mitochondrial Retrograde Signaling Through Activation of the MAPK Pathway
DNA and Cell Biology · 01.09.2026 · 45 (9) · 458-469
DOI: 10.1177/10445498261470989 ↗Kurz gefasst
Fachartikel in der Zeitschrift DNA and Cell Biology, online erschienen am 23.07.2026. Verfasst von Zenghui Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Yantai Yuhuangding Hospital, Yantai, China. Hauptthemen laut MEDLINE: Cisplatin, Uterine Cervical Neoplasms, Drug Resistance, Neoplasm, Mitochondria. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Chemoresistance constitutes a major cause of poor prognosis in advanced cervical cancer. Our previous studies have confirmed that Siglec-15 affects the progression of cervical cancer, whereas its role in regulating cervical cancer chemoresistance remains unexplored. This study investigates the role of Siglec-15 in cervical cancer chemoresistance and explores its mechanism. Siglec-15 expression and mitochondrial retrograde signaling levels were compared between parental and cisplatin-resistant cervical cancer cells. Lentiviral transfection was used to assess the functional effects of Siglec-15 modulation on the proliferation, apoptosis, and chemosensitivity of resistant cells. Further investigations were conducted to examine the effects of Siglec-15 on the mitogen-activated protein kinase (MAPK) signaling pathway, mitochondrial membrane potential, reactive oxygen species levels, and the expression of retrograde-related proteins. These in vitro findings were subsequently validated in vivo using a xenograft tumor model through immunohistochemistry, Terminal-deoxynucleotidyl transferase-mediated dUTP-nick-end labeling (TUNEL) assays, and western blotting. The results showed that Siglec-15 was markedly upregulated in cisplatin-resistant cervical cancer cells, correlating with enhanced mitochondrial retrograde signaling. Siglec-15 overexpression promoted cisplatin resistance and mitochondrial retrograde signaling, driving proliferation while inhibiting apoptosis. Mechanistically, Siglec-15 regulated mitochondrial retrograde signaling through activation of the MAPK pathway, thereby enhancing chemoresistance in drug-resistant cells. Elevated Siglec-15 expression enhances cisplatin resistance in cervical cancer cells by activating the MAPK pathway to promote mitochondrial retrograde signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, Yantai Yuhuangding Hospital, Yantai, China.
ORCID-Profile: Jing Wang
Zitieren
APA
Li, Z., Zhao, J., Hao, L., & Wang, J. (2026). Siglec-15 Enhances Cisplatin Resistance in Cervical Cancer Cells by Promoting Mitochondrial Retrograde Signaling Through Activation of the MAPK Pathway. DNA and Cell Biology, 45(9), 458-469. https://doi.org/10.1177/10445498261470989
Vancouver
Li Z, Zhao J, Hao L, Wang J. Siglec-15 Enhances Cisplatin Resistance in Cervical Cancer Cells by Promoting Mitochondrial Retrograde Signaling Through Activation of the MAPK Pathway. DNA and Cell Biology. 2026;45(9):458-469. doi:10.1177/10445498261470989
BibTeX
@article{Li2026,
author = {Li, Zenghui and Zhao, Junwei and Hao, Li and Wang, Jing},
title = {Siglec-15 Enhances Cisplatin Resistance in Cervical Cancer Cells by Promoting Mitochondrial Retrograde Signaling Through Activation of the MAPK Pathway},
journal = {DNA and Cell Biology},
year = {2026},
volume = {45},
number = {9},
pages = {458--469},
doi = {10.1177/10445498261470989}
}
EUVIMED